Global Hemophilia Treatment Market

Hemophilia Treatment Market

Hemophilia is a commonly inherited group of bleeding disorders in which there is a problem with the blood clotting process. It can reflect sudden bleeding, continuous bleeding after surgery, and injuries. It contains various clotting factors that help stop bleeding, if there is any mutation in these clotting genes that mutation can inhibit the clotting protein factor, necessary to form a blood clot. 

Market Size & Growth Rate:

The hemophilia treatment was valued at USD 11.2 billion in 2021 and is projected to reach USD 19.6 billion by 2027, with a CAGR of 5.4% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies. 

Market Dynamics:

• The hemophilia treatment market is expected to witness significant growth due to the increasing incidence of hemophilia. some statics shoes its anticipated platform, for instance 

• According to WFH (World Federation of Hemophilia) data-2021, the estimated prevalence at birth and the current live birth population across the globe, approximately 20,000 new cases of hemophilia is reported worldwide each year, of which 7,000 are severe.   

• In addition, the estimated and present world male population of 7.8 billion, the anticipated number of patients with hemophilia worldwide is 815,100, and about 276,900 of them are seriously ill.  

• However, based on CDC data, the majority of people with hemophilia are diagnosed at a very young age in the US. In addition, the approximate age at diagnosis is 36 months for mild hemophilia, 8 months for moderate hemophilia, and one month for severe hemophilia 

Market Drivers: 

• Increasing the demand for recombinant therapy 

• Amongst all, the recombinant therapy segment is estimated to hold the highest market share during the forecast period. 

• The manufacturing process of recombinant factor products is a laboratory methodology through recombinant technology. These products are not made from human blood. 

• Recombinant products are a safe and more effective method than plasma-derived products due to the low risk of blood borne infection  

• Increasing development and approvals of novel products in the recombinant segment for hemophilia. For instance, 

• In September 2021, Aviva Systems Biology Company launched its new protein-on-demand semi-custom recombinant protein portfolio for extensive research 

• In April 2020, LFB received FDA approval for Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment hemophilia  

• The growing prevalence of hemophilia A segment 

• The increase in research and development activities 

Challenges: 

• The side effects of the medication are anticipated to hamper the market growth 

• The adverse effects of bleeding disorder therapeutics are anticipated to inhibit market growth during the forecast period. For instance, the use of coagulation factor concentrates in the treatment of hemophilia, it may enhance the alloantibodies growth that work against factor VIII and factor IX.  

• The growth of such alloantibodies occurs in around 15% to 35% of patients linked with hemophilia A. Although about 50% of factor VIII and factor IX inhibitors are in the lower range, high-range inhibitors can lead to the increased impact of hemophilia, resulting in a major risk of excessive bleeding to the patient 

• Moreover, treatment using plasma-derived products can increase the risks of transmitting blood-borne pathogens such as prions and HIV, if the screening process is not conducted appropriately. 

• The high cost of hemophilia treatment will hamper the growth of the market   

• Shifting to recombinant therapy solutions to replace the plasma derived therapy products 

Competitive Landscape:

CSL Behring (U.S.), Grifols International (U.S.), Octapharma (Switzerland), Pfizer (U.S.), Biogen Idec, Xenetic Biosciences (U.S.), Sanofi (France), Cangene Corporation (Canada), Alnylam Pharmaceuticals (U.S.)Amgen U.S), Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.),  Prestige Consumer Healthcare Inc. (U.S.), Thea Laboratories (France),  Wellona Pharma (India),   Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan) 

Key Developments:

Competitors in the global hemophilia treatment market are engaged in regulatory approvals, the development of new services, and acquisition & collaborative agreements with other companies. A few expansion strategies are adopted by players operating in the hemophilia treatment market 

• In February 2020, Novo Nordisk launched Esperoct, an anti-hemophilic factor in the U.S. for the treatment of hemophilia in adults & children with hemophilia A. 

• In March 2019, Biotest AG received regulatory approval from 13 European countries for its product offering for the treatment of Hemophilia 

• In December 2019, Bayer AG agreed to collaborate for three-year with the children’s hospital. “The development of small molecules to treat hemophilia” is the main motto of collaboration. 

Regional Analysis:

North America has the largest haemophilia treatment market and will maintain its major market throughout the forecast period. Owing growing consumer awareness of the value of curing various forms of hemophilia disorders is also one of the major signs approach for new revenue platforms and growing R&D activities for the treatment of various hemophilia disorders is also expected to rise the growth potential. The increase in the number of patients diagnosed with hemophilia disorders and their awareness is driving the market growth Americas patients with bleeding disorders including haemophilia A & B were identified to be 55,287 in 2020 and this number is expected to reach 103,006 during the forecast period. In addition, the wide range of factor VIII is nearly 17% used for hemophilia A treatment, particularly in countries such as the United States and Canada. And a few more factors also enhance the growth of the market in this region like most people with hemophilia are diagnosed at a very young age. Based on CDC data, the median age at diagnosis is 36 months for people with mild hemophilia, 8 months for those with moderate hemophilia, and 1 month for those with severe hemophilia. 

Europe also remains a favorable region similar to the North American region. In recent times there is increased use of hemophilia treatments due to the rising number of bleeding disorder patients in these regions. For instance, according to data sources, the number of patients with bleeding disorders is expected to reach 81,306 during the forecast period from the identified number of patients 65,778 in 2020.The rising aging population, lifestyle factors, and increasing awareness of healthcare are some of the key driving factors for the growth of the global bleeding disorder treatment market. Moreover, the presence of highly skilled researchers, a developed R&D ecosystem, and support from government agencies and regulatory bodies are the major driving factors in Europe. 

Asia-Pacific: In the Asia-Pacific region, China and India are anticipated to be the fast emerging markets due to a large patient pool, the rising awareness through government organizations about the various bleeding disorders & rising expenditure to improve healthcare infrastructure.For instance, India has identified 22,594 people with hemophilia, and 507 people with other bleeding disorders in 2020. Furthermore, the rising R&D investment for the development of hemophilia products is anticipated to boost the bleeding disorder treatment market across the region. 

Middle East & Africa: For the coming few years, MEA regions are considered to be the lucrative market for the bleeding disorders treatment market. The growth in this region can be attributed to increasing initiatives by local governments for increasing access to healthcare, rising disposable income, and increasing the focus of global players toward emerging economies. 

Latin America: From the initiates by many government & health ministries, pharmaceutical companies, and NGOs conduct health programs and camps to educate the people and raise awareness to the market players distributing free samples and products for educating the people and promoting their drugs is anticipated to propel the hemophilia treatments during the forecast years.                                                                                                                                                                              For instance, the Wilson Center’s prestigious Latin American program provides insightful and actionable research for policymakers, private sector leaders, journalists, and public intellectuals in the United States and Latin America. 

Market Segmentation: 

• The global hemophilia treatment market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Disease Type 

• Hemophilia A 

• Hemophilia B 

• Von Willebrand Disease (vWD) 

• The global bleeding disorders market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Drug Therapy 

• Plasma Derived therapy 

• Recombinant therapy 

• Desmopressin Acetate 

• Antifibrinolytics 

What is Bleeding Disorders Treatment Market Report about? 

The hemophilia treatment market report discusses the commercial and clinical activity associated with applications. It provides insights on the total size of the potential opportunity, key segments driving growth, key challenges faced, and a thorough analysis of market competition by product, geography, indication, and forecasts through 2027. Detailed coverage of the approved hemophilia treatment, including regulatory approvals, pricing, reimbursement, and market penetration                                                                                                                                                                  So, a new investor can potentially gain information about hemophilia treatment companies, their key products, their core strategy, key trends in the hemophilia treatment market, and more. 

The hemophilia treatment market report is essential for all stakeholders including research companies, manufacturing companies, distribution companies, government agencies, and others. 

• Capitalize on rapidly emerging trends 

• Optimize decision-making 

• Reduce company risk 

• Approach partners/investors for collaboration or funding 

• Implement an informed and advantageous business strategy in 2022 

• Detailed coverage of the approved nuclear medicine therapeutics, including regulatory approvals, pricing, reimbursement, and market penetration 

• Profiles of leading & upcoming hemophilia treatment competitors composing the global marketplace